Product Description
A first-in-class FcRn pipeline candidate under development by Argenx. (Sourced from: https://argenx.com/news/2026/press-release-3216531)
Mechanisms of Action: FcRn Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: argenx
Company Location: Europe
Company Founding Year: 2008
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07377396 |
ARGX-124-1-HV-1001 | P1 |
Not yet recruiting |
Healthy Volunteers |
2026-12-31 |
50% |
2026-01-30 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|